Cinarizine - instructions for use, dose, side effects, contraindications

1 tablet contains: Active substance: Cinnarizine 25.0 mg. Excipients: lactose monohydrate (sugar milk) - 79.70 mg, microcrystalline cellulose - 25.00 mg, corn starch - 15.00 mg, povidone (polyvinylpyrrolidone) 3.0 mg, silicon dioxide colloid - 0.80 mg, magnesium stearate - 1, 50 mg.

Description:

tablets white or white with a creamy shade of color, flat-cylindrical with a risk and chamfer.

Pharmacotherapeutic group:The blocker of "slow" calcium channels.

ATX: & nbsp

N.07.C.A.02 Cinnarizine

Pharmacodynamics:

Selective blocker slow calcium channels, reduces the entry of calcium ions into cells and reduces their content in the depot of the plasmolemma, reduces the tone of the smooth muscles of arterioles, enhances the vasodilating effect of carbon dioxide. Immediately affecting the smooth muscles of blood vessels, reduces their response to nutrients (adrenaline, norepinephrine, dopamine, angiotensin, vasopressin). It has a vasodilating effect (especially with respect to cerebral vessels), without having a significant effect on blood pressure. It shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system. It is effective both in the initial and in chronic insufficiency of cerebral circulation (including in patients in the residual stage of ischemic stroke). In patients with impaired peripheral circulation improves blood supply to organs and tissues (including myocardium). Increases the elasticity of erythrocyte membranes, their ability to deform, reduces the viscosity of the blood.Increases muscle resistance to hypoxia.

Pharmacokinetics:

The drug is resorbed in the stomach and intestines. The maximum concentration in the blood plasma after oral administration after 1-3 hours. The connection of Cinnarizine with plasma proteins is 91%. Completely metabolized in the liver (via dealkylation). The half-life is 4 hours. It is excreted in the form of metabolites: 1/3 - kidneys and 2/3 - with fecal masses.

Indications:

Ischemic stroke, post-stroke conditions (including after hemorrhagic stroke), condition after craniocerebral trauma, dyscirculatory encephalopathy, vestibular disorders (including Meniere's disease, dizziness, tinnitus, nystagmus, nausea and vomiting of labyrinthine origin ), prevention of kinetosis ("road disease" - sea and air sickness), migraine (prevention of seizures), senile dementia; disorders of peripheral circulation ("intermittent" lameness, obliterating atherosclerosis, obliterating thromboangiitis (Burger's disease), Raynaud's disease, diabetic angiopathy, thrombophlebitis, trophic disorders (including trophic and varicose ulcers, pre-gangrenous conditions).

Contraindications:

Hypersensitivity, pregnancy, lactation.

Carefully:With caution in Parkinson's disease.

Dosing and Administration:

Inside, preferably after a meal. If the circulation of the brain is disturbed, 25-50 mg (1-2 tablets) three times a day; when peripheral circulation is disturbed - 50-75 mg (2-3 tablets) three times a day; with vestibular disorders - 25 mg three times a day; with kinetosis ("road" disease): adults - 25 mg for half an hour before the road (if necessary, repeated intake of 25 mg after 6 hours). The dose for children is ½ the dose recommended by the adult.

With high sensitivity to the drug, treatment starts with ½ dose, increasing it gradually. The course of treatment is from several weeks to several months.

Side effects:

From the nervous system: drowsiness, fatigue, headache, extrapyramidal disorders (limb tremor and increased muscle tone, hypokinesia).

Co side of the digestive system: dry mouth, pain in the epigastric region, dyspepsia, cholestatic jaundice.

From the skin: sweating, development of lupus-like syndrome, red flat lichen (extremely rare), skin rash.

Other: Allergic reactions, lowering blood pressure, increasing body weight.

Overdose:The maximum recommended dose should not exceed 225 mg (9 tablets) per day. In case of overdose there is no specific antidote, it is necessary to do a gastric lavage and take Activated carbon. Treatment is symptomatic.

Interaction:

Strengthens the effect of alcohol and sedatives. At simultaneous application with nootropic, antihypertensive and vasodilating agents strengthens their effect, and with simultaneous application with drugs prescribed for arterial hypotension - reduces their effect.

Special instructions:

At the beginning of treatment should be refrained from potentially dangerous activities that require increased concentration of attention and psychomotor reactions, as well as from drinking alcohol.

In connection with the presence of antihistamine effect, cinnarizine can affect the result in the case of anti-doping control of athletes (false positive result), and cinnarizine can neutralize positive reactions in conducting skin diagnostic tests (4 days before the study treatment should be canceled).

With prolonged use, it is recommended that a check examination of liver function, kidney function, and peripheral blood picture is recommended.

Patients suffering from Parkinson's disease should be appointed only in cases where the benefits from his appointment exceed the possible risk of deterioration.

Effect on the ability to drive transp. cf. and fur:

At the beginning of treatment, one should refrain from potentially dangerous activities requiring increased concentration of attention and psychomotor reactions.

Form release / dosage:Tablets of 0.025 g.

Packaging:

For 10, 50 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

By 10, 20, 30, 40, 50 or 100 tablets in cans of polymeric for medicines.

One jar or 1, 2, 3, 4, 5 or 10 contour mesh packages together with the instruction for use are placed in a cardboard package (bundle).

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:2 years.

Terms of leave from pharmacies:On prescription

Registration number:P N002934 / 01

Date of registration:08.12.2008

The owner of the registration certificate:ATOLL, LLC ATOLL, LLC Russia

Manufacturer: & nbsp

OZONE, LLC Russia

Information update date: & nbsp09.10.2015

Illustrated instructions

Instructions

Cinnarizine (Cinnarizine)